Improved treatment of nicotine addiction and emerging pulmonary drug delivery.
Nicotine addiction remains the leading cause of death and disease in developed and developing nations and a major cause of mortality around the world. Currently, nicotine replacement therapies (NRTs), bupropion, and varenicline are approved by the regulatory agencies as first-line treatments for nicotine addiction. Emerging evidence indicates that varenicline and bupropion have some therapeutic limitations for treating nicotine addiction with oral route of administration. Thus, continued investigation of innovative drug delivery for nicotine addiction remains a critical priority. This review will discuss some novel strategies and future directions for pulmonary drug delivery, an emerging route of administration for smoking cessation. It is anticipated that the advancement of knowledge on pulmonary drug delivery will provide better management for nicotine addiction and other addictive disorders.
Pharmacy Discipline, Faculty of Science and Technology, Queensland University of Technology, Brisbane, QLD, Australia.
Nazrul
N
Islam
Shafiqur
S
Rahman
D016503:Drug Delivery Systems; D006801:Humans; D008168:Lung / Q000378:metabolism*; D009538:Nicotine / Q000008:administration & dosage; D016540:Smoking Cessation / Q000379:methods; D014029:Tobacco Use Disorder / Q000188:drug therapy*
D009538:Nicotine